Boosting NAD+ Blunts Toll-Like Receptor-4 Induced Type-I Interferon in Control and Systemic Lupus Erythematosus Monocytes

Objective

To explore the anti-inflammatory effects of NR in monocytes (a type of white blood cell; immune cell) extracted from young, healthy subjects following supplementation. Additionally, the findings were tested in ex vivo in monocytes extracted from patients with systemic lupus erythematosus (SLE).

Study Design

Ex Vivo:
Monocytes were extracted from young, healthy subjects and patients with SLE and then treated with NR

In Vivo:
Randomized, double-blind, placebo-controlled, pilot study in 35 young, healthy subjects

Dose

1000 mg

Duration

1 week

Key Outcomes

Ex Vivo:

  • NR reduced cytokine expression and type-I interferon (IFN) signaling (which plays an important role in the human immune response) in monocytes from healthy subjects and SLE patients.

In Vivo:

  • NR supplementation increased whole blood NAD+ levels, as well as levels of related NAD+ metabolites.

  • NR supplementation also replicated the effects observed with ex-vivo NR administration, resulting in a similar reduction in type-I IFN signaling in the young, healthy subjects.

Clinical, Inflammation/Immune HealthANAD Staff